Global Antiepileptic Drugs research
Global Antiepileptic Drugs research

Antiepileptic Drugs Comprehensive Study by Drug (First Generation, Second Generation, Pipeline Drugs), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Spectrum (Narrow Spectrum, Broad Spectrum) Players and Region - Global Market Outlook to 2026

Antiepileptic Drugs Market Segmented into XX Submarkets. | Forecast Years: 2020- 2026  

May 2021 Edition 239 Pages 164 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Antiepileptic Drugs?
Epilepsy is a nervous system (neurological) disorder in which brain movement becomes anomalous, causing seizures or periods of abnormal behavior, sensations, and in some cases loss of awareness. Anyone can develop epilepsy. Epilepsy affects both male and female of all races, ethnic foundations and ages. Seizure symptoms can vary widely. Some people with epilepsy basically gaze blankly for some seconds during a seizure, while others repeatedly jerk their arms or legs. Having a single seizure doesn't mean you have got epilepsy. At least two unprovoked seizures are generally required for an epilepsy diagnosis. Antiepileptic drugs are medications that decrease the recurrence of epileptic seizures. Antiepileptic drugs (AEDs) are progressively utilized for the treatment of several non-epileptic neurological conditions & psychiatric disorders.

The market study is broken down and major geographies with country level break-up.

The rising number of players expected to enter the global market is predicted to enhance the competition level as well as encourage the growth of the overall market in the near future. Players are anticipated to focus on the development of new compounds, which is likely to encourage the growth of the global market throughout the forecast period. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Antiepileptic Drugs market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GW Pharmaceuticals plc (United Kingdom), Jazz pharmaceuticals (Ireland), Eisai Co., Ltd (Japan), Novartis AG (Switzerland), GlaxoSmithKline Plc (United Kingdom), Johnson & Johnson Service, Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer, Inc. (United States) and Sanofi S.A. (France) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sumitomo Dainippon Pharma Co. Ltd. (Japan), Mylan N.V. (United States), Bausch Health Companies Inc. (United States) and UCB S.A. (Belgium).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Antiepileptic Drugs market by Type, Application and Region.

On the basis of geography, the market of Antiepileptic Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug, the sub-segment i.e. First Generation will boost the Antiepileptic Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Antiepileptic Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Antiepileptic Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Spectrum, the sub-segment i.e. Narrow Spectrum will boost the Antiepileptic Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
On May 5, 2021- Jazz Pharmaceuticals announced the completion of acquisition of GW Pharmaceuticals plc, a pioneer in the science, development and commercialization of cannabinoid-based prescription drugs.
On 20 April 2021, GW Pharmaceuticals plc, a world pioneer in discovering, developing & delivering regulatory approved cannabis-based medications, announced that the European Commission (EC) has approved the Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures related with TSC, for patients two years of age & older. and Eisai Co., Ltd. announced that it has been received approval from the European Commission for the use of its in-house built and developed anti-epileptic agent (AED) Fycompa® in the treatment of pediatric patients.


Market Trend
  • Increased R&D Activities by Pharmaceutical Companies

Market Drivers
  • Increasing Neurological Disorder
  • Advancement in Drug Modification

Opportunities
  • Advancement in Chemical Compounds of the medicines

Restraints
  • Rising generic competition

Challenges
  • Increasing Side-Effects of Medicine
  • Shortage of Medicines in the Pharmacies


Key Target Audience
Drugs Manufacturers, Industry Association, Downstream Vendors, Marketing & Consulting firms, Venture Capitalists, Government & Regulatory Bodies and Traders/Suppliers & Distributors

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as GW Pharmaceuticals plc (United Kingdom), Jazz pharmaceuticals (Ireland), Eisai Co., Ltd (Japan), Novartis AG (Switzerland), GlaxoSmithKline Plc (United Kingdom), Johnson & Johnson Service, Inc. (United States), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer, Inc. (United States) and Sanofi S.A. (France) etc.

2. What would be the Market Size of Antiepileptic Drugs Market by 2026?
Analysts at AMA estimates Antiepileptic Drugs Market to reach USDXXX by 2026.

3. Can we have customized study for Antiepileptic Drugs Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
Report Objectives / Segmentation Covered
By Drug
  • First Generation
  • Second Generation
  • Pipeline Drugs

By Route of Administration
  • Oral
  • Intravenous

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Spectrum
  • Narrow Spectrum
  • Broad Spectrum

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Neurological Disorder
      • 3.2.2. Advancement in Drug Modification
    • 3.3. Market Challenges
      • 3.3.1. Increasing Side-Effects of Medicine
      • 3.3.2. Shortage of Medicines in the Pharmacies
    • 3.4. Market Trends
      • 3.4.1. Increased R&D Activities by Pharmaceutical Companies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antiepileptic Drugs, by Drug, Route of Administration, Distribution Channel, Spectrum and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Antiepileptic Drugs (Value)
      • 5.2.1. Global Antiepileptic Drugs by: Drug (Value)
        • 5.2.1.1. First Generation
        • 5.2.1.2. Second Generation
        • 5.2.1.3. Pipeline Drugs
      • 5.2.2. Global Antiepileptic Drugs by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Intravenous
      • 5.2.3. Global Antiepileptic Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Antiepileptic Drugs by: Spectrum (Value)
        • 5.2.4.1. Narrow Spectrum
        • 5.2.4.2. Broad Spectrum
      • 5.2.5. Global Antiepileptic Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Antiepileptic Drugs (Volume)
      • 5.3.1. Global Antiepileptic Drugs by: Drug (Volume)
        • 5.3.1.1. First Generation
        • 5.3.1.2. Second Generation
        • 5.3.1.3. Pipeline Drugs
      • 5.3.2. Global Antiepileptic Drugs by: Route of Administration (Volume)
        • 5.3.2.1. Oral
        • 5.3.2.2. Intravenous
      • 5.3.3. Global Antiepileptic Drugs by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacies
        • 5.3.3.2. Retail Pharmacies
        • 5.3.3.3. Online Pharmacies
      • 5.3.4. Global Antiepileptic Drugs by: Spectrum (Volume)
        • 5.3.4.1. Narrow Spectrum
        • 5.3.4.2. Broad Spectrum
      • 5.3.5. Global Antiepileptic Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Antiepileptic Drugs (Price)
  • 6. Antiepileptic Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GW Pharmaceuticals plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Jazz pharmaceuticals (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eisai Co., Ltd (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson Service, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi S.A. (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Antiepileptic Drugs Sale, by Drug, Route of Administration, Distribution Channel, Spectrum and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Antiepileptic Drugs (Value)
      • 7.2.1. Global Antiepileptic Drugs by: Drug (Value)
        • 7.2.1.1. First Generation
        • 7.2.1.2. Second Generation
        • 7.2.1.3. Pipeline Drugs
      • 7.2.2. Global Antiepileptic Drugs by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Intravenous
      • 7.2.3. Global Antiepileptic Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Antiepileptic Drugs by: Spectrum (Value)
        • 7.2.4.1. Narrow Spectrum
        • 7.2.4.2. Broad Spectrum
      • 7.2.5. Global Antiepileptic Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Antiepileptic Drugs (Volume)
      • 7.3.1. Global Antiepileptic Drugs by: Drug (Volume)
        • 7.3.1.1. First Generation
        • 7.3.1.2. Second Generation
        • 7.3.1.3. Pipeline Drugs
      • 7.3.2. Global Antiepileptic Drugs by: Route of Administration (Volume)
        • 7.3.2.1. Oral
        • 7.3.2.2. Intravenous
      • 7.3.3. Global Antiepileptic Drugs by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacies
        • 7.3.3.2. Retail Pharmacies
        • 7.3.3.3. Online Pharmacies
      • 7.3.4. Global Antiepileptic Drugs by: Spectrum (Volume)
        • 7.3.4.1. Narrow Spectrum
        • 7.3.4.2. Broad Spectrum
      • 7.3.5. Global Antiepileptic Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Antiepileptic Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antiepileptic Drugs: by Drug(USD Million)
  • Table 2. Antiepileptic Drugs First Generation , by Region USD Million (2014-2019)
  • Table 3. Antiepileptic Drugs Second Generation , by Region USD Million (2014-2019)
  • Table 4. Antiepileptic Drugs Pipeline Drugs , by Region USD Million (2014-2019)
  • Table 5. Antiepileptic Drugs: by Route of Administration(USD Million)
  • Table 6. Antiepileptic Drugs Oral , by Region USD Million (2014-2019)
  • Table 7. Antiepileptic Drugs Intravenous , by Region USD Million (2014-2019)
  • Table 8. Antiepileptic Drugs: by Distribution Channel(USD Million)
  • Table 9. Antiepileptic Drugs Hospital Pharmacies , by Region USD Million (2014-2019)
  • Table 10. Antiepileptic Drugs Retail Pharmacies , by Region USD Million (2014-2019)
  • Table 11. Antiepileptic Drugs Online Pharmacies , by Region USD Million (2014-2019)
  • Table 12. Antiepileptic Drugs: by Spectrum(USD Million)
  • Table 13. Antiepileptic Drugs Narrow Spectrum , by Region USD Million (2014-2019)
  • Table 14. Antiepileptic Drugs Broad Spectrum , by Region USD Million (2014-2019)
  • Table 15. South America Antiepileptic Drugs, by Country USD Million (2014-2019)
  • Table 16. South America Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 17. South America Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 18. South America Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 19. South America Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 20. Brazil Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 21. Brazil Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 22. Brazil Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 23. Brazil Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 24. Argentina Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 25. Argentina Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 26. Argentina Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 27. Argentina Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 28. Rest of South America Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 29. Rest of South America Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 30. Rest of South America Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 31. Rest of South America Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 32. Asia Pacific Antiepileptic Drugs, by Country USD Million (2014-2019)
  • Table 33. Asia Pacific Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 34. Asia Pacific Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 35. Asia Pacific Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 36. Asia Pacific Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 37. China Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 38. China Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 39. China Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 40. China Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 41. Japan Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 42. Japan Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 43. Japan Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 44. Japan Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 45. India Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 46. India Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 47. India Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 48. India Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 49. South Korea Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 50. South Korea Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 51. South Korea Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 52. South Korea Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 53. Taiwan Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 54. Taiwan Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 55. Taiwan Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 56. Taiwan Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 57. Australia Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 58. Australia Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 59. Australia Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 60. Australia Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 61. Rest of Asia-Pacific Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 62. Rest of Asia-Pacific Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 63. Rest of Asia-Pacific Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 64. Rest of Asia-Pacific Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 65. Europe Antiepileptic Drugs, by Country USD Million (2014-2019)
  • Table 66. Europe Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 67. Europe Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 68. Europe Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 69. Europe Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 70. Germany Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 71. Germany Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 72. Germany Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 73. Germany Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 74. France Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 75. France Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 76. France Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 77. France Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 78. Italy Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 79. Italy Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 80. Italy Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 81. Italy Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 82. United Kingdom Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 83. United Kingdom Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 84. United Kingdom Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 85. United Kingdom Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 86. Netherlands Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 87. Netherlands Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 88. Netherlands Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 89. Netherlands Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 90. Rest of Europe Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 91. Rest of Europe Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 92. Rest of Europe Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 93. Rest of Europe Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 94. MEA Antiepileptic Drugs, by Country USD Million (2014-2019)
  • Table 95. MEA Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 96. MEA Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 97. MEA Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 98. MEA Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 99. Middle East Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 100. Middle East Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 101. Middle East Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 102. Middle East Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 103. Africa Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 104. Africa Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 105. Africa Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 106. Africa Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 107. North America Antiepileptic Drugs, by Country USD Million (2014-2019)
  • Table 108. North America Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 109. North America Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 110. North America Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 111. North America Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 112. United States Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 113. United States Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 114. United States Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 115. United States Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 116. Canada Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 117. Canada Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 118. Canada Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 119. Canada Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 120. Mexico Antiepileptic Drugs, by Drug USD Million (2014-2019)
  • Table 121. Mexico Antiepileptic Drugs, by Route of Administration USD Million (2014-2019)
  • Table 122. Mexico Antiepileptic Drugs, by Distribution Channel USD Million (2014-2019)
  • Table 123. Mexico Antiepileptic Drugs, by Spectrum USD Million (2014-2019)
  • Table 124. Antiepileptic Drugs Sales: by Drug(K Units)
  • Table 125. Antiepileptic Drugs Sales First Generation , by Region K Units (2014-2019)
  • Table 126. Antiepileptic Drugs Sales Second Generation , by Region K Units (2014-2019)
  • Table 127. Antiepileptic Drugs Sales Pipeline Drugs , by Region K Units (2014-2019)
  • Table 128. Antiepileptic Drugs Sales: by Route of Administration(K Units)
  • Table 129. Antiepileptic Drugs Sales Oral , by Region K Units (2014-2019)
  • Table 130. Antiepileptic Drugs Sales Intravenous , by Region K Units (2014-2019)
  • Table 131. Antiepileptic Drugs Sales: by Distribution Channel(K Units)
  • Table 132. Antiepileptic Drugs Sales Hospital Pharmacies , by Region K Units (2014-2019)
  • Table 133. Antiepileptic Drugs Sales Retail Pharmacies , by Region K Units (2014-2019)
  • Table 134. Antiepileptic Drugs Sales Online Pharmacies , by Region K Units (2014-2019)
  • Table 135. Antiepileptic Drugs Sales: by Spectrum(K Units)
  • Table 136. Antiepileptic Drugs Sales Narrow Spectrum , by Region K Units (2014-2019)
  • Table 137. Antiepileptic Drugs Sales Broad Spectrum , by Region K Units (2014-2019)
  • Table 138. South America Antiepileptic Drugs Sales, by Country K Units (2014-2019)
  • Table 139. South America Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 140. South America Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 141. South America Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 142. South America Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 143. Brazil Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 144. Brazil Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 145. Brazil Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 146. Brazil Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 147. Argentina Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 148. Argentina Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 149. Argentina Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 150. Argentina Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 151. Rest of South America Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 152. Rest of South America Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 153. Rest of South America Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 154. Rest of South America Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 155. Asia Pacific Antiepileptic Drugs Sales, by Country K Units (2014-2019)
  • Table 156. Asia Pacific Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 157. Asia Pacific Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 158. Asia Pacific Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 159. Asia Pacific Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 160. China Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 161. China Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 162. China Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 163. China Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 164. Japan Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 165. Japan Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 166. Japan Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 167. Japan Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 168. India Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 169. India Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 170. India Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 171. India Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 172. South Korea Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 173. South Korea Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 174. South Korea Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 175. South Korea Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 176. Taiwan Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 177. Taiwan Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 178. Taiwan Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 179. Taiwan Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 180. Australia Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 181. Australia Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 182. Australia Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 183. Australia Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 184. Rest of Asia-Pacific Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 185. Rest of Asia-Pacific Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 186. Rest of Asia-Pacific Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 187. Rest of Asia-Pacific Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 188. Europe Antiepileptic Drugs Sales, by Country K Units (2014-2019)
  • Table 189. Europe Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 190. Europe Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 191. Europe Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 192. Europe Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 193. Germany Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 194. Germany Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 195. Germany Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 196. Germany Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 197. France Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 198. France Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 199. France Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 200. France Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 201. Italy Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 202. Italy Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 203. Italy Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 204. Italy Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 205. United Kingdom Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 206. United Kingdom Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 207. United Kingdom Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 208. United Kingdom Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 209. Netherlands Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 210. Netherlands Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 211. Netherlands Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 212. Netherlands Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 213. Rest of Europe Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 214. Rest of Europe Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 215. Rest of Europe Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 216. Rest of Europe Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 217. MEA Antiepileptic Drugs Sales, by Country K Units (2014-2019)
  • Table 218. MEA Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 219. MEA Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 220. MEA Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 221. MEA Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 222. Middle East Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 223. Middle East Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 224. Middle East Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 225. Middle East Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 226. Africa Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 227. Africa Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 228. Africa Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 229. Africa Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 230. North America Antiepileptic Drugs Sales, by Country K Units (2014-2019)
  • Table 231. North America Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 232. North America Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 233. North America Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 234. North America Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 235. United States Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 236. United States Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 237. United States Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 238. United States Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 239. Canada Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 240. Canada Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 241. Canada Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 242. Canada Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 243. Mexico Antiepileptic Drugs Sales, by Drug K Units (2014-2019)
  • Table 244. Mexico Antiepileptic Drugs Sales, by Route of Administration K Units (2014-2019)
  • Table 245. Mexico Antiepileptic Drugs Sales, by Distribution Channel K Units (2014-2019)
  • Table 246. Mexico Antiepileptic Drugs Sales, by Spectrum K Units (2014-2019)
  • Table 247. Company Basic Information, Sales Area and Its Competitors
  • Table 248. Company Basic Information, Sales Area and Its Competitors
  • Table 249. Company Basic Information, Sales Area and Its Competitors
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Antiepileptic Drugs: by Drug(USD Million)
  • Table 257. Antiepileptic Drugs First Generation , by Region USD Million (2021-2026)
  • Table 258. Antiepileptic Drugs Second Generation , by Region USD Million (2021-2026)
  • Table 259. Antiepileptic Drugs Pipeline Drugs , by Region USD Million (2021-2026)
  • Table 260. Antiepileptic Drugs: by Route of Administration(USD Million)
  • Table 261. Antiepileptic Drugs Oral , by Region USD Million (2021-2026)
  • Table 262. Antiepileptic Drugs Intravenous , by Region USD Million (2021-2026)
  • Table 263. Antiepileptic Drugs: by Distribution Channel(USD Million)
  • Table 264. Antiepileptic Drugs Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 265. Antiepileptic Drugs Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 266. Antiepileptic Drugs Online Pharmacies , by Region USD Million (2021-2026)
  • Table 267. Antiepileptic Drugs: by Spectrum(USD Million)
  • Table 268. Antiepileptic Drugs Narrow Spectrum , by Region USD Million (2021-2026)
  • Table 269. Antiepileptic Drugs Broad Spectrum , by Region USD Million (2021-2026)
  • Table 270. South America Antiepileptic Drugs, by Country USD Million (2021-2026)
  • Table 271. South America Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 272. South America Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 273. South America Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 274. South America Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 275. Brazil Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 276. Brazil Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 277. Brazil Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 278. Brazil Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 279. Argentina Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 280. Argentina Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 281. Argentina Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 282. Argentina Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 283. Rest of South America Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 284. Rest of South America Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 285. Rest of South America Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 286. Rest of South America Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 287. Asia Pacific Antiepileptic Drugs, by Country USD Million (2021-2026)
  • Table 288. Asia Pacific Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 289. Asia Pacific Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 290. Asia Pacific Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 291. Asia Pacific Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 292. China Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 293. China Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 294. China Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 295. China Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 296. Japan Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 297. Japan Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 298. Japan Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 299. Japan Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 300. India Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 301. India Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 302. India Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 303. India Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 304. South Korea Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 305. South Korea Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 306. South Korea Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 307. South Korea Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 308. Taiwan Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 309. Taiwan Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 310. Taiwan Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 311. Taiwan Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 312. Australia Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 313. Australia Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 314. Australia Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 315. Australia Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 316. Rest of Asia-Pacific Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 317. Rest of Asia-Pacific Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 318. Rest of Asia-Pacific Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 319. Rest of Asia-Pacific Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 320. Europe Antiepileptic Drugs, by Country USD Million (2021-2026)
  • Table 321. Europe Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 322. Europe Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 323. Europe Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 324. Europe Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 325. Germany Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 326. Germany Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 327. Germany Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 328. Germany Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 329. France Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 330. France Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 331. France Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 332. France Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 333. Italy Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 334. Italy Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 335. Italy Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 336. Italy Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 337. United Kingdom Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 338. United Kingdom Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 339. United Kingdom Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 340. United Kingdom Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 341. Netherlands Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 342. Netherlands Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 343. Netherlands Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 344. Netherlands Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 345. Rest of Europe Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 346. Rest of Europe Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 347. Rest of Europe Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 348. Rest of Europe Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 349. MEA Antiepileptic Drugs, by Country USD Million (2021-2026)
  • Table 350. MEA Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 351. MEA Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 352. MEA Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 353. MEA Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 354. Middle East Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 355. Middle East Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 356. Middle East Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 357. Middle East Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 358. Africa Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 359. Africa Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 360. Africa Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 361. Africa Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 362. North America Antiepileptic Drugs, by Country USD Million (2021-2026)
  • Table 363. North America Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 364. North America Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 365. North America Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 366. North America Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 367. United States Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 368. United States Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 369. United States Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 370. United States Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 371. Canada Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 372. Canada Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 373. Canada Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 374. Canada Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 375. Mexico Antiepileptic Drugs, by Drug USD Million (2021-2026)
  • Table 376. Mexico Antiepileptic Drugs, by Route of Administration USD Million (2021-2026)
  • Table 377. Mexico Antiepileptic Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 378. Mexico Antiepileptic Drugs, by Spectrum USD Million (2021-2026)
  • Table 379. Antiepileptic Drugs Sales: by Drug(K Units)
  • Table 380. Antiepileptic Drugs Sales First Generation , by Region K Units (2021-2026)
  • Table 381. Antiepileptic Drugs Sales Second Generation , by Region K Units (2021-2026)
  • Table 382. Antiepileptic Drugs Sales Pipeline Drugs , by Region K Units (2021-2026)
  • Table 383. Antiepileptic Drugs Sales: by Route of Administration(K Units)
  • Table 384. Antiepileptic Drugs Sales Oral , by Region K Units (2021-2026)
  • Table 385. Antiepileptic Drugs Sales Intravenous , by Region K Units (2021-2026)
  • Table 386. Antiepileptic Drugs Sales: by Distribution Channel(K Units)
  • Table 387. Antiepileptic Drugs Sales Hospital Pharmacies , by Region K Units (2021-2026)
  • Table 388. Antiepileptic Drugs Sales Retail Pharmacies , by Region K Units (2021-2026)
  • Table 389. Antiepileptic Drugs Sales Online Pharmacies , by Region K Units (2021-2026)
  • Table 390. Antiepileptic Drugs Sales: by Spectrum(K Units)
  • Table 391. Antiepileptic Drugs Sales Narrow Spectrum , by Region K Units (2021-2026)
  • Table 392. Antiepileptic Drugs Sales Broad Spectrum , by Region K Units (2021-2026)
  • Table 393. South America Antiepileptic Drugs Sales, by Country K Units (2021-2026)
  • Table 394. South America Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 395. South America Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 396. South America Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 397. South America Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 398. Brazil Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 399. Brazil Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 400. Brazil Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 401. Brazil Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 402. Argentina Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 403. Argentina Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 404. Argentina Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 405. Argentina Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 406. Rest of South America Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 407. Rest of South America Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 408. Rest of South America Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 409. Rest of South America Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 410. Asia Pacific Antiepileptic Drugs Sales, by Country K Units (2021-2026)
  • Table 411. Asia Pacific Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 412. Asia Pacific Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 413. Asia Pacific Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 414. Asia Pacific Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 415. China Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 416. China Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 417. China Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 418. China Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 419. Japan Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 420. Japan Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 421. Japan Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 422. Japan Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 423. India Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 424. India Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 425. India Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 426. India Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 427. South Korea Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 428. South Korea Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 429. South Korea Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 430. South Korea Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 431. Taiwan Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 432. Taiwan Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 433. Taiwan Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 434. Taiwan Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 435. Australia Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 436. Australia Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 437. Australia Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 438. Australia Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 439. Rest of Asia-Pacific Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 440. Rest of Asia-Pacific Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 441. Rest of Asia-Pacific Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 442. Rest of Asia-Pacific Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 443. Europe Antiepileptic Drugs Sales, by Country K Units (2021-2026)
  • Table 444. Europe Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 445. Europe Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 446. Europe Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 447. Europe Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 448. Germany Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 449. Germany Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 450. Germany Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 451. Germany Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 452. France Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 453. France Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 454. France Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 455. France Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 456. Italy Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 457. Italy Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 458. Italy Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 459. Italy Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 460. United Kingdom Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 461. United Kingdom Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 462. United Kingdom Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 463. United Kingdom Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 464. Netherlands Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 465. Netherlands Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 466. Netherlands Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 467. Netherlands Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 468. Rest of Europe Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 469. Rest of Europe Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 470. Rest of Europe Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 471. Rest of Europe Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 472. MEA Antiepileptic Drugs Sales, by Country K Units (2021-2026)
  • Table 473. MEA Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 474. MEA Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 475. MEA Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 476. MEA Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 477. Middle East Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 478. Middle East Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 479. Middle East Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 480. Middle East Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 481. Africa Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 482. Africa Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 483. Africa Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 484. Africa Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 485. North America Antiepileptic Drugs Sales, by Country K Units (2021-2026)
  • Table 486. North America Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 487. North America Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 488. North America Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 489. North America Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 490. United States Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 491. United States Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 492. United States Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 493. United States Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 494. Canada Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 495. Canada Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 496. Canada Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 497. Canada Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 498. Mexico Antiepileptic Drugs Sales, by Drug K Units (2021-2026)
  • Table 499. Mexico Antiepileptic Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 500. Mexico Antiepileptic Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 501. Mexico Antiepileptic Drugs Sales, by Spectrum K Units (2021-2026)
  • Table 502. Research Programs/Design for This Report
  • Table 503. Key Data Information from Secondary Sources
  • Table 504. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antiepileptic Drugs: by Drug USD Million (2014-2019)
  • Figure 5. Global Antiepileptic Drugs: by Route of Administration USD Million (2014-2019)
  • Figure 6. Global Antiepileptic Drugs: by Distribution Channel USD Million (2014-2019)
  • Figure 7. Global Antiepileptic Drugs: by Spectrum USD Million (2014-2019)
  • Figure 8. South America Antiepileptic Drugs Share (%), by Country
  • Figure 9. Asia Pacific Antiepileptic Drugs Share (%), by Country
  • Figure 10. Europe Antiepileptic Drugs Share (%), by Country
  • Figure 11. MEA Antiepileptic Drugs Share (%), by Country
  • Figure 12. North America Antiepileptic Drugs Share (%), by Country
  • Figure 13. Global Antiepileptic Drugs: by Drug K Units (2014-2019)
  • Figure 14. Global Antiepileptic Drugs: by Route of Administration K Units (2014-2019)
  • Figure 15. Global Antiepileptic Drugs: by Distribution Channel K Units (2014-2019)
  • Figure 16. Global Antiepileptic Drugs: by Spectrum K Units (2014-2019)
  • Figure 17. South America Antiepileptic Drugs Share (%), by Country
  • Figure 18. Asia Pacific Antiepileptic Drugs Share (%), by Country
  • Figure 19. Europe Antiepileptic Drugs Share (%), by Country
  • Figure 20. MEA Antiepileptic Drugs Share (%), by Country
  • Figure 21. North America Antiepileptic Drugs Share (%), by Country
  • Figure 22. Global Antiepileptic Drugs share by Players 2019 (%)
  • Figure 23. Global Antiepileptic Drugs share by Players (Top 3) 2019(%)
  • Figure 24. Global Antiepileptic Drugs share by Players (Top 5) 2019(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. GW Pharmaceuticals plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. GW Pharmaceuticals plc (United Kingdom) Revenue: by Geography 2019
  • Figure 28. Jazz pharmaceuticals (Ireland) Revenue, Net Income and Gross profit
  • Figure 29. Jazz pharmaceuticals (Ireland) Revenue: by Geography 2019
  • Figure 30. Eisai Co., Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Eisai Co., Ltd (Japan) Revenue: by Geography 2019
  • Figure 32. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Novartis AG (Switzerland) Revenue: by Geography 2019
  • Figure 34. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2019
  • Figure 36. Johnson & Johnson Service, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Johnson & Johnson Service, Inc. (United States) Revenue: by Geography 2019
  • Figure 38. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 39. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2019
  • Figure 40. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. Pfizer, Inc. (United States) Revenue: by Geography 2019
  • Figure 42. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 43. Sanofi S.A. (France) Revenue: by Geography 2019
  • Figure 44. Global Antiepileptic Drugs: by Drug USD Million (2021-2026)
  • Figure 45. Global Antiepileptic Drugs: by Route of Administration USD Million (2021-2026)
  • Figure 46. Global Antiepileptic Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 47. Global Antiepileptic Drugs: by Spectrum USD Million (2021-2026)
  • Figure 48. South America Antiepileptic Drugs Share (%), by Country
  • Figure 49. Asia Pacific Antiepileptic Drugs Share (%), by Country
  • Figure 50. Europe Antiepileptic Drugs Share (%), by Country
  • Figure 51. MEA Antiepileptic Drugs Share (%), by Country
  • Figure 52. North America Antiepileptic Drugs Share (%), by Country
  • Figure 53. Global Antiepileptic Drugs: by Drug K Units (2021-2026)
  • Figure 54. Global Antiepileptic Drugs: by Route of Administration K Units (2021-2026)
  • Figure 55. Global Antiepileptic Drugs: by Distribution Channel K Units (2021-2026)
  • Figure 56. Global Antiepileptic Drugs: by Spectrum K Units (2021-2026)
  • Figure 57. South America Antiepileptic Drugs Share (%), by Country
  • Figure 58. Asia Pacific Antiepileptic Drugs Share (%), by Country
  • Figure 59. Europe Antiepileptic Drugs Share (%), by Country
  • Figure 60. MEA Antiepileptic Drugs Share (%), by Country
  • Figure 61. North America Antiepileptic Drugs Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GW Pharmaceuticals plc (United Kingdom)
  • Jazz pharmaceuticals (Ireland)
  • Eisai Co., Ltd (Japan)
  • Novartis AG (Switzerland)
  • GlaxoSmithKline Plc (United Kingdom)
  • Johnson & Johnson Service, Inc. (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Pfizer, Inc. (United States)
  • Sanofi S.A. (France)
Additional players considered in the study are as follows:
Sumitomo Dainippon Pharma Co. Ltd. (Japan) , Mylan N.V. (United States) , Bausch Health Companies Inc. (United States) , UCB S.A. (Belgium)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation